# Hejun Liu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9763425/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 34 papers | 2,719 citations | 516215 16 h-index | 433756 31 g-index |
| 55 all docs | 55 docs citations | 55 times ranked | 5073 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Neutralizing Antibodies to SARSâ€CoVâ€2 Selected from a Human Antibody Library Constructed Decades Ago. Advanced Science, 2022, 9, e2102181. | 5.6 | 14 |
| 2 | Nipah Virus V Protein Binding Alters MDA5 Helicase Folding Dynamics. ACS Infectious Diseases, 2022, 8, 118-128. | 1.8 | 3 |
| 3 | Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120976119. | 3.3 | 27 |
| 4 | Protective neutralizing epitopes in SARSâ€CoVâ€2. Immunological Reviews, 2022, 310, 76-92. | 2.8 | 23 |
| 5 | Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology, 2022, 23, 960-970. | 7.0 | 39 |
| 6 | Superimmunity by pan-sarbecovirus nanobodies. Cell Reports, 2022, 39, 111004. | 2.9 | 13 |
| 7 | Neutralizing Antibody Response to Sarbecovirus Is Delayed in Sequential Heterologous Immunization. Viruses, 2022, 14, 1382. | 1.5 | 2 |
| 8 | A broad and potent neutralization epitope in SARS-related coronaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, . | 3.3 | 34 |
| 9 | The intrinsically disordered protein TgIST from Toxoplasma gondii inhibits STAT1 signaling by blocking cofactor recruitment. Nature Communications, 2022, 13, . | 5.8 | 15 |
| 10 | Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochemical and Biophysical Research Communications, 2021, 538, 192-203. | 1.0 | 165 |
| 11 | Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science, 2021, 371, . | 6.0 | 304 |
| 12 | Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. Cell Reports, 2021, 35, 109173. | 2.9 | 46 |
| 13 | Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 2021, 373, 818-823. | 6.0 | 309 |
| 14 | A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host and Microbe, 2021, 29, 806-818.e6. | 5.1 | 49 |
| 15 | Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Reports, 2021, 35, 109109. | 2.9 | 21 |
| 16 | Homologous and heterologous serological response to the Nâ€terminal domain of SARSâ€CoVâ€2 in humans and mice. European Journal of Immunology, 2021, 51, 2296-2305. | 1.6 | 7 |
| 17 | Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413. | 5.8 | 79 |
| 18 | COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nature Communications, 2021, 12, 6097. | 5.8 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. ACS Central Science, 2021, 7, 1863-1873. | 5.3 | 20 |
| 20 | A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell, 2020, 183, 1058-1069.e19. | 13.5 | 305 |
| 21 | An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Reports, 2020, 33, 108274. | 2.9 | 152 |
| 22 | Structural basis of a shared antibody response to SARS-CoV-2. Science, 2020, 369, 1119-1123. | 6.0 | 536 |
| 23 | Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity, 2020, 53, 1272-1280.e5. | 6.6 | 185 |
| 24 | Structural basis of recognition of SARS-CoV-2 by neutralizing antibodies isolated from convalescent patients. Acta Crystallographica Section A: Foundations and Advances, 2020, 76, a202-a202. | 0.0 | 0 |
| 25 | A Secreted Viral Nonstructural Protein Determines Intestinal Norovirus Pathogenesis. Cell Host and Microbe, 2019, 25, 845-857.e5. | 5.1 | 57 |
| 26 | Crystallographic Analysis of the Catalytic Mechanism of Phosphopantothenoylcysteine Synthetase from Saccharomyces cerevisiae. Journal of Molecular Biology, 2019, 431, 764-776. | 2.0 | 4 |
| 27 | Conservation of Structure and Immune Antagonist Functions of Filoviral VP35 Homologs Present in Microbat Genomes. Cell Reports, 2018, 24, 861-872.e6. | 2.9 | 16 |
| 28 | Structural Insights into the Association of Hif1 with Histones H2A-H2B Dimer and H3-H4 Tetramer. Structure, 2016, 24, 1810-1820. | 1.6 | 14 |
| 29 | Structural insights into yeast histone chaperone Hif1: a scaffold protein recruiting protein complexes to core histones. Biochemical Journal, 2014, 462, 465-473. | 1.7 | 14 |
| 30 | Structures of enzymeâ€“intermediate complexes of yeast Nit2: insights into its catalytic mechanism and different substrate specificity compared with mammalian Nit2. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 1470-1481. | 2.5 | 16 |
| 31 | Structural insights into the role of the Chl4â€“Iml3 complex in kinetochore assembly. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 2412-2419. | 2.5 | 7 |
| 32 | Structural insights into decreased enzymatic activity induced by an insert sequence in mannonate dehydratase from Gram negative bacterium. Journal of Structural Biology, 2012, 180, 327-334. | 1.3 | 5 |
| 33 | A Sars-Cov-2 Neutralizing Antibody Protects from Lung Pathology in a Covid-19 Hamster Model. SSRN Electronic Journal, 0, , . | 0.4 | 3 |
| 34 | Dynamics of B-Cell Repertoires and Emergence of Cross-Reactive Responses in COVID-19 Patients with Different Disease Severity. SSRN Electronic Journal, 0, , . | 0.4 | 2 |